Health TrialsbyHealthPanel

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

REC-7735 in Participants With Solid Tumors

The study is designed to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of REC-7735 in participants with unresectable, locally advanced, or metastatic PIK3CA-H1047R mutated solid tumors.

Participants needed: 90
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Recursion Pharmaceuticals Inc.Updated: Sep 29, 2026Locations: 3
Eligibility criteria

Participants have histologically-confirmed unresectable, locally advanced, or me... [+2]

Participants have experienced disease progression with a phosphoinositide 3-kina... [+9]

Read more
Status: Recruiting

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.

Participants needed: 170
Trial details
Phase: Phase 1, Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: Recursion Pharmaceuticals Inc.Updated: Aug 20, 2026Locations: 7
Eligibility criteria

Have histologically-confirmed unresectable, locally advanced, or metastatic sele... [+3]

Received treatment with another RBM39 degrader [+1]

Read more
Status: Recruiting

Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

This is a multicenter, two-part trial in participants with FAP.

Participants needed: 67
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Recursion Pharmaceuticals Inc.Updated: Jun 5, 2026Locations: 17
Eligibility criteria

Male or female and ≥ 18 years of age [+19]

Has any clinically significant laboratory abnormality, medical or psychiatric il... [+34]

Read more